Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing
Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Who this might be right for
Breast Cancer
Genentech, Inc. 285